Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review

摘要: Kaposi sarcoma (ks) is a vascular tumour caused by oncogenic human herpesvirus type 8; it often occurs with hiv-associated immunosuppression. Numerous cellular signalling pathways are involved in the pathogenesis of ks, among which receptor tyrosine kinases such as c-Kit and platelet-derived growth factor receptors play an important role. Imatinib mesylate, kinase inhibitor, has resulted partial regression ks lesions one third treated patients, but its mechanism action remains unclear. Here, we report case white man recurrent despite well-suppressed hiv infection multiple chemotherapies who received imatinib showed complete sustained response. To our knowledge, this first showing value management context long-lasting control adequate quantitative CD4 recovery. Our indicates that can be treatment option for highly chemoresistant patients on long-term antiretroviral therapy.